Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
WARMINSTER, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it has scheduled its first quarter 2024 financial results and corporate update for Thursday, May 2, 2024. The schedule for the press release and conference call/webcast are as follows:
賓夕法尼亞州沃明斯特，2024年4月18日（GLOBE NEWSWIRE）——Arbutus Biopharma Corporation（納斯達克股票代碼：ABUS）是一家臨床階段的生物製藥公司，利用其廣泛的病毒學專業知識爲慢性乙型肝炎病毒（ChbV）感染患者開發功能性治療方法，今天宣佈，計劃於2024年5月2日星期四發佈2024年第一季度財務業績和公司最新情況。新聞稿和電話會議/網絡直播的時間表如下：
| • | Q1 2024 Press Release: | Thursday, May 2, 2024 at 7:30 a.m. ET |
| • | Q1 2024 Conference Call/Webcast: | Thursday, May 2, 2024 at 8:45 a.m. ET |
| • | 2024 年第一季度新聞稿： | 美國東部時間 2024 年 5 月 2 日星期四上午 7:30 |
| • | 2024 年第一季度電話會議/網絡直播： | 美國東部時間 2024 年 5 月 2 日星期四上午 8:45 |
To dial-in for the conference call by phone, please register using the following link: Registration Link. A live webcast of the conference call can be accessed through the Investors section of Arbutus' website at www.arbutusbio.com.
要通過電話撥入電話會議，請使用以下鏈接進行註冊： 註冊鏈接。電話會議的網絡直播可通過Arbutus網站的 “投資者” 欄目觀看，網址爲 www.arbutusbio.com。
An archived webcast will be available on the Arbutus website after the event.
活動結束後，Arbutus網站上將提供存檔的網絡直播。
About Arbutus
關於 Arbutus
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). We believe the key to success in developing a functional cure involves suppressing HBV DNA, reducing surface antigen, and boosting HBV-specific immune responses. Our pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729) and an oral PD-L1 inhibitor, AB-101. Imdusiran has generated meaningful clinical data demonstrating an impact on both surface antigen reduction and reawakening of the HBV-specific immune response. Imdusiran is currently in two Phase 2a combination clinical trials. AB-101 is currently being evaluated in a Phase 1a/1b clinical trial. For more information, visit www.arbutusbio.com.
Arbutus Biopharma Corporation（納斯達克股票代碼：ABUS）是一家臨床階段的生物製藥公司，利用其豐富的病毒學專業知識來識別和開發具有不同作用機制的新型療法，這些療法可以結合爲慢性乙型肝炎病毒（ChbV）患者提供功能性治癒。我們認爲，成功開發功能性治療方法的關鍵是抑制乙肝病毒DNA、減少表面抗原和增強乙肝病毒特異性免疫反應。我們內部開發的專有化合物產品線包括一種核糖核酸治療藥物 imdusiran (AB-729) 和口服 PD-L1 抑制劑 AB-101。Imdusiran已經生成了有意義的臨床數據，表明它對錶面抗原的減少和乙肝病毒特異性免疫反應的恢復都有影響。Imdusiran目前正在進行兩項2a期聯合臨床試驗。AB-101 目前正在 1a/1b 期臨床試驗中進行評估。欲了解更多信息，請訪問 www.arbutusbio.com。
Contact Information
聯繫信息
Investors and Media
投資者和媒體
Lisa M. Caperelli
Vice President, Investor Relations
Phone: 215-206-1822
Email: lcaperelli@arbutusbio.com
麗莎·M·卡佩雷利
投資者關係副總裁
電話：215-206-1822
電子郵件： lcaperelli@arbutusbio.com
譯文內容由第三人軟體翻譯。